Serum Metabolomic Profiling Identifies Key Metabolic Signatures Associated With Pathogenesis of Alcoholic Liver Disease in Humans

Zhihong Yang, Praveen Kusumanchi, Ruth A. Ross, Laura Heathers, Kristina Chandler, Adepeju Oshodi, Themis Thoudam, Feng Li, Li Wang, Suthat Liangpunsakul – 20 February 2019 – Alcoholic liver disease (ALD) develops in a subset of heavy drinkers (HDs). The goals of our study were to (1) characterize the global serum metabolomic changes in well‐characterized cohorts of controls (Cs), HDs, and those with alcoholic cirrhosis (AC); (2) identify metabolomic signatures as potential diagnostic markers, and (3) determine the trajectory of serum metabolites in response to alcohol abstinence.

Predicting Postoperative Liver Dysfunction Based on Blood‐Derived MicroRNA Signatures

Patrick Starlinger, Hubert Hackl, David Pereyra, Susanna Skalicky, Elisabeth Geiger, Michaela Finsterbusch, Dietmar Tamandl, Christine Brostjan, Thomas Grünberger, Matthias Hackl, Alice Assinger – 19 February 2019 – There is an urgent need for an easily assessable preoperative test to predict postoperative liver function recovery and thereby determine the optimal time point of liver resection, specifically as current markers are often expensive, time consuming, and invasive.

Are There Upper Limits in Tumor Burden for Down‐Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All‐Comers Protocol

Jasmine Sinha, Neil Mehta, Jennifer L. Dodge, Eduard Poltavskiy, John Roberts, Francis Yao – 19 February 2019 – Patients with hepatocellular carcinoma (HCC) within the University of California, San Francisco down‐staging (UCSF‐DS) criteria (one lesion > 5 cm and ≤ 8 cm; two to three lesions each ≤ 5 cm; or four to five lesions each ≤ 3 cm with total tumor diameter ≤ 8 cm) who achieved successful down‐staging (DS) to Milan criteria had similar outcomes after liver transplantation (LT) compared with HCC initially meeting the Milan criteria.

Ex Vivo Hepatocyte Reprograming Promotes Homology‐Directed DNA Repair to Correct Metabolic Disease in Mice After Transplantation

Caitlin J. VanLith, Rebekah M. Guthman, Clara T. Nicolas, Kari L. Allen, Yuanhang Liu, Jennifer A. Chilton, Zachariah P. Tritz, Scott L. Nyberg, Robert A. Kaiser, Joseph B. Lillegard, Raymond D. Hickey – 15 February 2019 – Ex vivo CRISPR/Cas9‐mediated gene editing in hepatocytes using homology‐directed repair (HDR) is a potential alternative curative therapy to organ transplantation for metabolic liver disease.

Subscribe to